NCT01766960

Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease

Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: University of North Carolina, Chapel Hill · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

One-third of the U.S. population suffers from non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by diabetes and obesity, and is becoming more common. Although many people have this disease, the change in how the liver handles drugs and compounds in the body has not been studied. The purpose of this study is to investigate how advanced NAFLD changes the ability of the liver to handle both endogenous and exogenous compounds.

Conditions

• Fatty Liver

Interventions

Type	Name	Description
OTHER	High fat meal	A high fat breakfast will be administered to induce gall bladder emptying.
DRUG	Morphine	Five milligrams of intravenous morphine will be administered.

Timeline

• Start date: 2012-11-01
• Primary completion: 2014-03-01
• Completion: 2014-06-01
• First posted: 2013-01-11
• Last updated: 2016-03-03

Locations

1 site across 1 country: United States